Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler prescribed for COPD and asthma. Trelegy Ellipta has interactions with some other drugs ...
The inhaler is packaged within a moisture-protective foil tray with a desiccant and a peelable lid in the following packs: Trelegy Ellipta 100/62.5/25 mcg 30 inhalations (60 blisters) and Trelegy ...
The FDA has approved GlaxoSmithKline’s Trelegy Ellipta inhaler for asthma in adults, adding to its existing use in chronic obstructive pulmonary disease (COPD), stealing a march on rivals ...
Trelegy is a key drug for GSK, and analysts predict peak sales in excess of $1billion. The company needs new revenues in respiratory diseases, as its ageing blockbuster inhaler Advair will face ...
GlaxoSmithKline won approval for a three-drug COPD inhaler, Trelegy Ellipta, in 2017. 3D medical animation services have emerged as a groundbreaking tool in the healthcare industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback